February 14, 2020 10:49 AM ESTUpdated 04:13 PM

AstraZeneca sweeps two cancer drugs to the scrap heap; Epizyme nabs priority review for second rare cancer NDA

ENDPOINTS

→ AstraZeneca swept out two early-stage cancer drugs in its Q4 call on Friday. Out to the dustbin goes the anti-ASCT2 antibody-drug conjugate MEDI7247 and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca sweeps two cancer drugs to the scrap heap; Epizyme nabs priority review for second rare cancer NDA

ENDPOINTS

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Novo Nordisk claims late-stage MASH victory, continuing GLP-1's expansion

Biogen brings in medical chief as CFO plans retirement; MacroGenics CEO announces departure

Essa’s shares tank as it looks for options after abandoning prostate cancer drug

Exclusive: Blood stem cell therapy maker Garuda gets new CEO, adds $47M

FDA removes hold on three CARsgen CAR-T trials; Ono passes on itolizumab

UCB's anti-tau Alzheimer's program fails Phase 2 primary endpoint, but highlights positive secondaries

As­traZeneca sweeps two can­cer drugs to the scrap heap; Epizyme nabs pri­or­i­ty re­view for sec­ond rare can­cer NDA

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

AstraZeneca sweeps two cancer drugs to the scrap heap; Epizyme nabs priority review for second rare cancer NDA